ZhuZhou QianJin Pharmaceutical Co Ltd

Qianjin Pharmaceutical released its 2026 interim report, with total operating revenue of 1.918 billion yuan, up 5.52% year on year. Net profit attributable to the parent company was 181 million yuan, up 41.59% year on year, marking five consecutive years of growth. Net cash inflow from operating activities was 53.0658 million yuan, an increase of 97.5329 million yuan year on year, achieving three consecutive years of growth. The company's asset-liability ratio was 33.01%, gross margin was 49.68%, return on equity was 5.98%, and diluted earnings per share was 0.37 yuan, up 21.98% year on year. The number of shareholders was 33,300, and the top ten shareholders held 44.18% of the total share capital.

Qianjin Pharmaceutical announced plans to distribute a cash dividend of 1.8 yuan per 10 shares, including tax, with an estimated total payout of 88.6 million yuan. In the first half of 2026, the company achieved revenue of 1.918 billion yuan and net profit attributable to the parent of 181 million yuan.

Qianjin Pharmaceutical released its 2026 interim report. First-half net profit attributable to the parent company was 181 million yuan, up 41.6% year on year. Operating revenue was 1.92 billion yuan, up 5.5% year on year. Net profit attributable to the parent after deducting non-recurring items was 176 million yuan, up 49.4% year on year. Net operating cash flow was 53.07 million yuan, up 219.3% year on year. Second-quarter operating revenue was 948 million yuan, up 16.6% year on year, and net profit attributable to the parent was 106 million yuan, up 41.9% year on year. The company focuses on the research, production and sale of Chinese patent medicines, chemical drugs and feminine hygiene products, and invested in 117 research projects during the reporting period.

Qianjin Pharmaceutical disclosed its 2026 half-year report. In the first half, it achieved operating revenue of 1.918 billion yuan, up 5.52% year on year. Net profit attributable to shareholders of the listed company was 181 million yuan, up 41.59% year on year. Basic earnings per share were 0.3674 yuan. The company plans to distribute a cash dividend of 1.8 yuan per 10 shares, tax included. During the reporting period, revenue from the company's pharmaceutical production segment increased.

Qianjin Pharmaceutical announced that its subsidiaries Qianjin Xiangjiang Pharmaceutical and Qianjin Xieli Pharmaceutical have received Drug Registration Certificates issued by the National Medical Products Administration for minoxidil liniment, ezetimibe tablets, amlodipine benazepril capsules, and ursodeoxycholic acid capsules.

Qianjin Pharmaceutical and its subsidiary Hunan Qianjin Xiangjiang Pharmaceutical had a total of four products tentatively selected in the 12th national centralized drug procurement. The tentatively selected products include dydrogesterone tablets, iguratimod tablets, baricitinib tablets, and alogliptin benzoate tablets. The procurement cycle runs from the implementation date of the selection results until December 31, 2029. In the first quarter of 2026, Qianjin Pharmaceutical achieved revenue of 970 million yuan and net profit attributable to the parent company of 75 million yuan.

Qianjin Pharmaceutical's subsidiary, Qianjin Xiangjiang Pharmaceutical, has received the Drug Registration Certificate for Baclofen Tablets. The drug is indicated for severe but reversible muscle spasms caused by multiple sclerosis, and may have some efficacy for spasms caused by other spinal cord diseases. In 2025, the total sales of Baclofen Tablets in China's medical and retail markets reached 247 million yuan. As of the announcement date, Qianjin Xiangjiang Pharmaceutical's cumulative R&D investment in this drug was 5.88 million yuan. Qianjin Pharmaceutical achieved revenue of 970 million yuan in the first quarter of 2026, with a net profit attributable to the parent company of 75 million yuan.